These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16467076)

  • 1. Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage.
    Hodi FS
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):673-8. PubMed ID: 16467076
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor antigen expression in melanoma varies according to antigen and stage.
    Barrow C; Browning J; MacGregor D; Davis ID; Sturrock S; Jungbluth AA; Cebon J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):764-71. PubMed ID: 16467087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma vaccines: achievements and perspectives.
    Brichard VG; Gérard C
    Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma gene expression and clinical course.
    Vourc'h-Jourdain M; Volteau C; Nguyen JM; Khammari A; Dreno B
    Arch Dermatol Res; 2009 Oct; 301(9):673-9. PubMed ID: 19326132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma cancer vaccines and anti-tumor T cell responses.
    Vujanovic L; Butterfield LH
    J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor antigens as surrogate markers and targets for therapy and vaccines.
    Dalgleish A; Pandha H
    Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Sondak VK; Sabel MS; Mulé JJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An immunocytochemical investigation of antigen expression by skin melanoma cells cultured for vaccine production].
    Moiseenko VM; Danilova AB; Danilov AO; Turkevich EA; Baldueva IA; Matsko DE
    Vopr Onkol; 2008; 54(3):303-14. PubMed ID: 18652234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-recognition and tumor response to immunotherapy.
    Ernstoff MS
    J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer/testis genes expression in human melanoma cell lines.
    Mikhaylova IN; Kovalevsky DA; Morozova LF; Golubeva VA; Cheremushkin EA; Lukashina MI; Voronina ES; Burova OS; Utyashev IA; Kiselev SL; Demidov LV; Beabealashvilli RSh; Baryshnikov AY
    Melanoma Res; 2008 Oct; 18(5):303-13. PubMed ID: 18781128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic profiles of individual-matched pairs of primary and melanoma metastases.
    Meije CB; Swart GW; Lepoole C; Das PK; Van den Oord JJ
    Hum Pathol; 2009 Oct; 40(10):1399-407. PubMed ID: 19386352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The unfulfilled promise of melanoma vaccines.
    Livingston P
    Clin Cancer Res; 2001 Jul; 7(7):1837-8. PubMed ID: 11448892
    [No Abstract]   [Full Text] [Related]  

  • 15. SEMG-1 expression in early stage chronic lymphocytic leukemia.
    Ahmed SU; Meklat F; Shahriar M; Zhang J; Mastulov S; Giannakouros T; Jewell A; Zhang Y; Lim SH
    Cytotherapy; 2009; 11(2):238-44. PubMed ID: 19241194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor antigens].
    Tiuriaeva II
    Tsitologiia; 2008; 50(3):189-209. PubMed ID: 18664121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
    Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
    Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma vaccines.
    Chapman PB
    Semin Oncol; 2007 Dec; 34(6):516-23. PubMed ID: 18083375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide and dendritic cell vaccines.
    Slingluff CL; Engelhard VH; Ferrone S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2342s-2345s. PubMed ID: 16609056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cancer-fighting implant?
    Marron K
    Lab Anim (NY); 2009 Mar; 38(3):72. PubMed ID: 19229213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.